In Ottawa this spring, Dr. Richard Hatchett made a case that feels increasingly urgent: we can build a better mousetrap for pandemic threats. The CEO of the Coalition for Epidemic Preparedness Innovations (CEPI) has been pitching the "100 Days Mission," an ambitious project designed to develop and manufacture vaccines within 100 days of identifying a novel pandemic pathogen. The timing of his visit proved both coincidental and prescient—even as he spoke to Canadian officials, news was breaking of a hantavirus outbreak spreading aboard a cruise ship, a fresh reminder that infectious threats emerge with little warning and even less mercy.
"These kinds of threats are continually and unpredictably emerging," Hatchett observed, and the evidence was unfolding in real time. The hantavirus outbreak, which had begun the previous month and captured global attention, served as an unintended but powerful illustration of why his initiative matters. Viruses do not wait for us to be ready. They do not ask permission or announce their arrival. What they do is expose the gaps in our defenses—and the 100 Days Mission is designed to close those gaps.
The concept itself is straightforward but transformative: instead of the years typically required to develop, test, and manufacture a new vaccine, CEPI is working toward a model where scientists and manufacturers can deliver a working vaccine within a hundred days of a pathogen's emergence. For diseases like hantavirus, Ebola, or the next unknown threat, that acceleration could mean the difference between containing an outbreak and watching it spread globally. It is a race against biology itself, powered by preemptive research, coordinated global infrastructure, and the kind of political will that Hatchett was in Ottawa seeking.
His credentials for leading this charge run deep. Before taking the helm at CEPI in 2017, Hatchett served as acting director of the Biomedical Advanced Research and Development Authority (BARDA), a U.S. federal agency laser-focused on developing medical countermeasures for mass public health emergencies. That experience in the machinery of pandemic preparedness informed his vision: you cannot innovate under pressure alone. You must build the platforms, the partnerships, and the scientific groundwork while the world is still calm.
The hantavirus outbreak underscored Hatchett's central argument: pandemic preparedness is not abstract policy work. It is the difference between a contained incident and a cascade. Countries investing in vaccine preparedness and committing to global cooperation are not hedging their bets—they are protecting their citizens and their neighbors. The virus on that cruise ship was a reminder that borders are porous, that modern travel collapses distance, and that any outbreak anywhere is potentially an outbreak everywhere.
What Hatchett is pitching in capitals like Ottawa is a shift in mindset: from reactive to proactive, from hoping we get lucky to building the capability to respond fast. The 100 Days Mission is not a guarantee against future pandemics. But it is a promise that when the next unknown pathogen emerges—and it will—the world will have invested in the tools and coordination needed to fight back in days, not months or years. In an age of emerging infectious threats, that promise matters more than ever.